Abstract Cefazolin (CFZ) is highly and saturably bound to human serum albumin (HSA) in adults. We aim to describe CFZ protein binding and its covariates in neonates. In neonates to whom intravenous CFZ (50 mg/kg) was administered prior to a surgical procedure, total and unbound CFZ plasma concentrations (mg/l) were determined at 0.5, 2, 4 and 8 h after CFZ administration. Linear and multiple regression analyses were used to document covariates of unbound CFZ fraction. The Wilcoxon signed-rank test was used for the paired analysis of unbound CFZ fractions. In 40 patients with a median weight of 2,767 (range 830-4,200) g and a postmenstrual age (PMA) of 39 (25-45) weeks, 131 samples were collected. The median unbound CFZ fraction was 0.39 (0.10-0.73). Linear regression of unbound CFZ fraction versus unbound CFZ plasma concentration (R 2 00.39) had a slope significantly different from zero (p<0.001). In a multiple regression analysis, albuminaemia, total CFZ concentration, indirect bilirubinaemia and PMA resulted in an R 2 value of 0.496. The median unbound CFZ fraction at the peak concentration (0.46, range 0.28-0.69) was significantly higher compared to the trough level (0.36, range 0.17-0.73) (p<0.001). The between-and within-patient saturability of CFZ plasma protein binding were documented in neonates. The median unbound CFZ fraction in neonates is higher than in adults and depends partly on albuminaemia, total CFZ concentration, indirect bilirubinaemia and PMA. Integration of CFZ protein binding in future pharmacokinetic/pharmacodynamic research is warranted in order to optimise neonatal CFZ dosing. We recommend protein binding assessment in the neonatal pharmacokinetic evaluation of highly protein-bound or clinically relevant drugs.
Introduction
Cefazolin (CFZ), a first-generation cephalosporin, interferes with bacterial cell wall synthesis and covers especially Gram-positive bacteria. CFZ is administered parenterally and mainly used as prophylactic agent for surgical procedures in children and adults [1] . The therapeutic use of CFZ has also been described and was effective in 87 % of neonates with a coagulase-negative staphylococcal (CoNS) lateonset sepsis [2] .
In plasma, CFZ is bound to human serum albumin (HSA) [3] [4] [5] . Protein binding influences drug disposition but also drug action, since only the unbound drug is pharmacologically active [6] . Furthermore, unbound drug concentrations in plasma are assumed to reflect drug concentrations at the effect site. CFZ protein binding has been studied in pregnant woman [1] , adult (surgical) patients [7, 8] and morbidly obese patients [9] . Within the adult population, important intra-and inter-individual variability as well as the concentration-dependency (saturability) of CFZ protein binding has been documented [1, 7] . Drug disposition in neonates differs from adults based on their physiological characteristics (e.g. large extracellular fluid volume, low glomerular filtration rate, immaturity of liver functions associated with a higher incidence of indirect hyperbilirubinaemia), aspects of protein binding (e.g. hypoalbuminaemia), as well as specific pathological processes (e.g. growth restriction, congenital cardiopathy). Furthermore, ontogeny (reflected by age and weight) needs to be considered. Since protein binding is of relevance in the pharmacologic [i.e. pharmacokinetic (PK) and pharmacodynamic (PD)] evaluation of CFZ, the aim of the present study was to describe CFZ protein binding and its covariates in neonates.
Methods

Ethics, drug dosing and clinical characteristics
All patients were admitted to the Neonatal Intensive Care Unit of the University Hospitals Leuven, Belgium. The study was registered at ClinicalTrials.gov (NCT01295606) and approved by the ethical board of our hospital. After informed written consent from the parents, neonates were considered for inclusion if CFZ (Cefazolin Sandoz®, Sandoz, Vilvoorde, Belgium) was intravenously administered over 30 min as the routine prophylactic drug prior to a surgical procedure. As standard care, CFZ 50 mg/kg is administered at induction of all procedures. Based on a predefined schedule depending on the duration of surgery, foreign body implantation or the contamination risk, (an) additional CFZ dose(s) are administered with an 8-h interval. Clinical characteristics recorded at inclusion were gestational age at birth (GA), postmenstrual age (PMA), postnatal age (PNA), birth weight, current body weight (BW), cardiopathy (yes/no), gender and indication for CFZ prophylaxis. Albuminaemia (g/l), indirect serum bilirubin concentrations (mg/dl) and serum creatinine (mg/dl) in a time interval of 24 h before or after the first CFZ administration were extracted from clinical files. Threshold values for hyperbilirubinaemia are based on earlier reported cut-off values according to the PNA, to adapt for the normal postnatal transient increase with subsequent decrease in neonatal life [10] . Plasma free fatty acids concentrations (FFA, mmol/l) were additionally determined on study samples at the end of the study.
Plasma sampling
To determine the total and unbound CFZ plasma concentrations, we aimed to collect blood samples at fixed time points, i.e. 0.5, 2, 4 and 8 h after the first CFZ administration and, subsequently, at 8-h intervals prior to each scheduled CFZ administration. In clinical practice, the number of samples collected in each patient was limited, since the maximum total volume of blood available for sampling per individual patient was 1 ml/kg.
Drug assay
The initial high-performance liquid chromatography (HPLC) method was developed in our laboratory and reported in the literature [1] . The method was adapted for the measurement of CFZ in small-volume plasma samples of neonates.
To determine the total CFZ plasma concentration, to 0.1 ml of plasma were added the following: 10 μl standard CFZ dilutions in water (final concentration range 0.1-100 mg/l), 10 μl cefoxitin dilution (100 mg/l) in water and 0.1 ml 0.1 M ammonium acetate buffer pH 4.0. After vortexing and centrifuging for 5 min at 1,800×g, these samples were ready for application to the solid-phase extraction columns (Oasis HLB 30 mg, 1 ml).
The solid-phase extraction was performed with a Vac Elut SPS24 vacuum extraction system. The columns were activated with 2× 1 ml methanol and 2× 1 ml water, applying slight vacuum to the columns. The prepared standards, controls or samples were subsequently passed through the columns over a time period of 2 to 3 min. Then, 1 ml water was applied and vacuum maintained for 2 min, followed by 1 ml methanol/water (80/20, v/v) and, again, vacuum maintained for a further 2 min. Elution of the columns was performed with 2× 0.5 ml of methanol (+0.2 % triethylamine). The eluates were evaporated with an airstream in a water bath at 45°C and the dried residues dissolved in 200 μl mobile phase. Injection volumes varied between 20 and 50 μl.
To determine the unbound fraction of CFZ, to 0.1 ml of plasma was added 10 μl of 1 M HEPES buffer pH 6.0. The samples were vortexed and incubated for 1 h in a water bath at 37°C. Ultrafiltration was performed with Centrifree micropartition devices in a fixed rotor centrifuge for 30 min at 1,100×g at room temperature (final temperature in the centrifuge was 32°C). The volume of the ultrafiltrate was adjusted to 0.1 ml with 0.5 % BSA in 0.9 % NaCl. After the addition of 10 μl of cefoxitin (100 mg/l) and 0.1 ml of 5 % trichloroacetic acid, vortexing for 15 s and waiting for 10 min, the samples were centrifuged for 8 min at 12,000×g. Standard curves were prepared in 0.5 % BSA in 0.9 % NaCl, instead of plasma. A quantity of 100 μl of the supernatant was transferred to injection vials and injected onto the analytical column. The HPLC conditions remained the same and method performance showed the same recovery and reproducibility as reported previously [1] .
Biochemical assays
Albumin (bromocresol green), indirect bilirubin and creatinine (enzymatic) were determined on Roche Modular P (Roche Diagnostics, Basel, Switzerland). Non-esterified fatty acids were determined with a kit from DiaSys (DiaSys Diagnostic Systems, Holzheim, Germany).
Statistical analysis
Statistical analysis was performed using SPSS (IBM statistical software, version 19) and MedCalc® (Mariakerke, Belgium). Clinical characteristics were reported by their median and range or incidence. CFZ plasma concentrations (mg/l) were also reported by median and range. Unbound CFZ fraction was calculated as the ratio of unbound to total drug concentrations, as reported in the literature. The impact of continuous and dichotomous covariates on unbound CFZ fraction was determined using linear regression and Mann-Whitney Utests, respectively. Significant results of the monovariate linear regression were entered in a multiple forward regression analysis. The within-patient comparison of unbound CFZ fraction at peak versus trough CFZ concentration was assessed using the Wilcoxon signed-rank test. For this paired analysis, only neonates with CFZ concentrations on both peak (0-2 h after the first CFZ administration) and trough (>6 h after the first CFZ administration but before the next CFZ administration, if scheduled) times were included. For different clinical conditions (i.e. albuminaemia <35 vs.≥35 g/l, albuminaemia <30 vs. ≥30 g/l, PMA <37 vs. ≥37 weeks, PNA <10 vs. ≥10 days and indirect hyperbilirubinaemia vs. no indirect hyperbilirubinaemia), the relationship between unbound and total CFZ concentrations was expressed using a regression equation.
Results
Forty neonates (male/female ratio 25/15) were included. The clinical characteristics and indications for CFZ administration are shown in Table 1 . Based on 131 samples, the median (range) total and unbound CFZ plasma concentrations were 100.63 (9.65-404.22) mg/l and 40 (2-261.38) mg/l, respectively. The median unbound CFZ fraction was 0.39 (0.10-0.73).
Linear regression of the unbound CFZ fraction as a function of the unbound CFZ plasma concentration resulted in an R 2 value of 0.39 (p<0.001) and a slope significantly different from zero (p<0.001) (Fig. 1) . Linear regression analysis was significant between unbound CFZ fraction and total CFZ concentration (R 2 00.10, p<0.001), PMA (R 2 00.29, p<0.001), PNA (R 2 00.17, p<0.001), GA (R 2 00.04, p00.018), albuminaemia (R 2 00.12, p<0.001) and indirect bilirubinaemia (R 2 00.10, p<0.001), but not between unbound CFZ fraction and plasma FFA concentration (R 2 00.001, p00.657). Unbound CFZ fraction was not significantly influenced by cardiopathy (Mann-Whitney U-test, p00.08), nor by gender (Mann-Whitney U-test, p00.31). In a multiple forward regression analysis, based on all (n0131) samples, four independent covariates of unbound CFZ fraction (PMA, albuminaemia, total CFZ concentration and indirect bilirubinaemia) resulted in an R 2 value of 0.496 (p<0.001). Linear regression graphs of the four individual covariates retained are shown in Fig. 2 a-d. Paired plasma samples were available in 29 neonates. The median peak and trough sampling times and corresponding CFZ concentrations are reported in Table 2 . The median (range) of the unbound CFZ fraction at peak level (0.46, 0.28-0.69) was significantly higher compared to trough level (0.36, 0.17-0.73) (p<0.001).
In Table 3 , we estimated the total CFZ concentrations needed when an unbound CFZ concentration of 8 mg/l is used as the minimum inhibitory concentration (MIC) for susceptible pathogens, e.g. CoNS [Clinical and Laboratory Estimates were provided for different clinical conditions. Considering the total study population, the unbound CFZ concentration was ≥8 mg/L in 128 of 131 samples (97.7 %).
Discussion
Effective treatment with CFZ requires the integration of protein binding, which will affect disposition, since only the unbound drug is responsible for antimicrobial action. We documented a median (range) unbound CFZ fraction of 0.39 (0.10-0.73) in neonates and established betweenpatient as well as within-patient saturability of CFZ protein binding. Neonatal unbound CFZ fraction in our study is higher than reported values in adults (0.25, 0.14-0.41 in pregnant woman and 0.19, 0.10-0.51 in non-pregnant adults) [1, 7] . We, hereby, confirm the findings of Deguchi et al., who reported a mean unbound CFZ fraction of 0.51 (± 0.17) in neonates and also referred to a significant difference in unbound CFZ fraction between newborns and children (0.22±0.03, n06) versus adults (0.11±0.02, n012) [12] . In addition to the paper of Deguchi et al., we explored covariates of the inter-individual variability in neonatal unbound CFZ fraction. Albuminaemia, total CFZ plasma concentration, indirect bilirubinaemia and PMA explained [1] . Since neonates frequently display a lower albuminaemia compared to children or adults, an elevated unbound drug fraction can be expected. Within the neonatal population, albuminaemia increases with age, reaching adult levels before the age of 5 months [13] . The variation of unbound CFZ fraction with total CFZ concentration confirms that the concept of CFZ protein binding saturability is also applicable to neonates, but saturation is reached sooner compared to other populations because of a lower binding capacity [7] . In addition to findings in adults, the covariates 'indirect bilirubinaemia' and 'PMA' were specific for neonatal CFZ protein binding. In early life, indirect hyperbilirubinaemia is common due to an increased production and decreased removal (by glucuronidation) of indirect bilirubin. Bilirubin displays an association constant 100 to 1,000 times greater than most drugs for albumin [13] . It can displace CFZ from plasma albumin, resulting in an increased unbound drug fraction in case of an increased indirect bilirubin level. Additionally, the binding of bilirubin to albumin can induce an allosteric effect on albumin, resulting in a decreased CFZ binding percentage [4, 12] . However, CFZ itself can also displace bilirubin from albumin binding sites [14] , suggesting that the competition between bilirubin and CFZ for albumin binding sites is a mutual interaction [15] . Our observation is an illustration of this competitive binding concept. Structural changes of albumin in pathological conditions or the possible influence of unknown endogenous inhibitors on albumin binding need further research.
PMA showed the strongest relation with unbound CFZ fraction (R 2 00.29). Changes in the neonatal plasma profile and body composition can partly be attributed to PMA and can influence drug protein binding [13] . The importance of age on neonatal protein binding was also documented for other compounds. Pullen et al. reported a significant correlation of neonatal flucloxacillin protein binding with age (gestational age, postconceptional age) [16] .
The impact of protein binding on CFZ PK and PD needs special attention. CFZ elimination occurs by the renal route (glomerular filtration and active tubular secretion). In general, higher protein binding is associated with lower drug elimination by tubular secretion and correlates negatively with glomerular filtration, because only the unbound drug is filtered [9, 17, 18] . Since a higher unbound CFZ fraction is documented in neonates, it is reasonable to postulate that clearance is proportionally higher compared to adults. However, the combination of an overall low glomerular filtration rate and less effective renal tubular functions in neonates makes it difficult to predict the effect of protein binding on neonatal CFZ clearance and needs further study.
Protein binding also affects the volume of distribution, because only the unbound drug can reach the extravascular space [19] . Deguchi et al. documented that inter-individual changes in the CFZ volume of distribution per body weight in neonates are mainly due to individual differences in the unbound CFZ plasma fraction [12] .
The efficacy of CFZ is related to the drug concentration at the receptor site (i.e. bacterial cell wall), but also to the time during which the drug concentration exceeds the MIC for a given pathogen [9, 18, 20] . Measurement of the total CFZ concentration without considering aspects of unbound CFZ fraction is, therefore, not reliable for estimating the PD effect. For prophylactic use, we aim for a time (T) > MIC of 100 %. In our study, 97.7 % of samples had an unbound CFZ concentration ≥8 mg/l, reflecting good prophylaxis for susceptible pathogens, e.g. CoNS [11] . For different patient subgroups, we provided the total CFZ concentration needed to exceed an unbound concentration of 8 mg/l (Table 3) . These estimates are based on the regression equation of the unbound versus total CFZ concentrations collected in our study population and illustrate variability in different clinical conditions. To introduce these results in clinical practice, further population modelling is needed. Since the unbound CFZ fraction is higher in neonates, lower doses (mg/kg) might theoretically be used to provide the same drug effect Table 3 Estimates of the total cefazolin (CFZ) concentration (mg/l) needed for a time above the minimum inhibitory concentration (T> MIC) of 100 % if an unbound CFZ concentration of 8 mg/l is used as the MIC value for susceptible pathogens, e.g. coagulase-negative staphylococci (CoNS) [11] . Estimates are based on the regression equations of the unbound versus total CFZ concentrations collected in our study population for different clinical conditions. Threshold values for hyperbilirubinaemia are >115 μmol/l if PNA<2 days, >155 μmol/L if PNA 2-5 days, >120 μmol/L if PNA 6-12 days, >80 μmol/l if PNA 13-19 days, >45 μmol/l if PNA 20-26 days and >10 μmol/l if PNA ≥27 days, as reported in the literature, to adapt for the normal postnatal increase and subsequent decrease of bilirubin in neonatal life [10] . as in adults, although final dosing guidelines should also consider CFZ distribution and clearance. We did not focus on CFZ PD but, rather, want to stress that the influence of protein binding on drug PD in neonates is of relevance beyond compound-specific observations. In general, a minor decrease in protein binding-for very highly (e.g. >90 %) protein-bound drugs-will have a major effect on the free drug proportion. For drugs with a high toxicity profile, this can result in altered (side)effects and the administration of lower drug doses has to be considered. For drugs with minor toxicity, like CFZ, we have to be aware that dose adaptations may result in ineffectivity or increased free bilirubin. Overall, data concerning protein binding, population-specific PK/PD, as well as drug characteristics have to be taken into account in future initiatives to optimise dosage regimens. Our study has its limitations, but also some strengths. Due to restrictions in blood volumes available for sampling in neonates, we could not collect all predefined samples in each patient. FFA can influence drug-albumin interaction [4, 21] ; however, FFA were not significant determinants of CFZ protein binding in our study and the concentrations were lower than earlier reported values in neonates and infants [13, 22] . This can be due to interferences of comedication and parenteral nutrition and sample handling [23] . Finally, a review of individual patient data showed that the highest values of total (404.22 mg/l) and unbound (261.38 mg/l) CFZ concentrations belonged to the same patient. The chart review indicated that this patient unintentionally received an additional CFZ dose 1.8 h after the induction dose. These limitations reflect the difficult balance between research aims and clinical care in the neonatal intensive care setting. We suggest that the strengths of our study are the relevant study size (40 neonates) and the repeated, focused sampling instead of opportunistic sampling strategies (e.g. Pullen et al., remnants), enabling paired analysis.
We conclude that albuminaemia, total CFZ concentration, indirect bilirubinaemia and PMA are the main covariates explaining 49.6 % of the inter-individual variability of neonatal CFZ protein binding. Between-and withinpatient saturability of CFZ protein binding were also documented in neonates, but, compared to adults, a higher unbound CFZ fraction was found in neonates. As a future perspective, the integration of CFZ protein binding aspects in PK/PD research is warranted in order to optimise neonatal CFZ dosing regimens. Since neonatal PK studies often assume a fixed degree of protein binding, we recommend the measurement of protein binding, especially for highly protein-bound and clinically relevant drugs. This needs to be studied among sufficient numbers of patients so as to give a reliable point estimate for the neonatal population, as well as a distribution for the extent of protein binding. These data could be included in further PK population modelling.
